Estrone
Price | Get Latest Price |
- Supply Ability: 500 Ton/Tons per Month
- Time:2021-07-09
Product Details
- Product NameEstrone
- CAS No.53-16-7
- EINECS No.200-164-5
- MFC18H22O2
- MW270.37
- InChIKeyDNXHEGUUPJUMQT-CBZIJGRNSA-N
- AppearanceCrystalline Powder or CrystalsWhite to almost white
- Water Solubility 0.03 g/L
- Melting point 258-260 °C(lit.)
- storage temp. room temp
- Boiling point 353.48°C (rough estimate)
- density 1.2360
Product Description
Estrone (E1, and also oestrone) is an estrogenic hormone secreted by the ovary as well as adipose tissue. Estrone is one of several natural estrogens, which also include estriol and estradiol. Estrone is the least abundant of the three hormones; estradiol is present almost always in the reproductive female body, and estriol is abundant primarily during pregnancy. Estrone is relevant to health and disease states because of its conversion to estrone sulfate, a long-lived derivative. Estrone sulfate acts as a reservoir that can be converted as needed to the more active estradiol. Estrone is the only estrogen which is present in any quantity in post-menopausal women.
In the 1930s, estrone was given via intramuscular injection to ovariectomized women in order to study its effects and to elucidate the biological properties of estrogens in humans. In these studies, prior to administration of estrone, amenorrhea, atrophy of the breasts (as well as flaccidity and small and non-erectile nipples), vagina, and endometrium, vaginal dryness, and subjective symptoms of ovariectomy (e.g., hot flashes, mood changes) were all present in the women. Treatment with estrone was found to dose- and time-dependently produce a variety of effects, including breast changes, reproductive tract changes of the vagina, cervix, and endometrium/uterus, and relief from the subjective symptoms of ovariectomy, as well as increased libido.
Breast changes specifically included enlargement and a sense of fullness, increased sensitivity and pigmentation of the nipples as well as nipple erection, tingling within the breast mammary glandular tissue, and aching and soreness of the breasts.Reproductive tract changes included increased growth, thickness, and differentiation of the endometrium, and reversal of vaginal and cervical atrophy, which were accompanied by increased congestion of the cervix and mucous discharge from the cervix, uterine cramps and needle-like pains, pelvic fullness, a "bearing-down" sensation, and increased vaginal lubrication, as well as uterine bleeding both during treatment and in the days following cessation of injections. Endometrial hyperplasia also occurred with sufficiently high dosages of estrone.
Specification
ANALYSIS
SPECIFICATION
RESULTS
Appearance
Fine powder
Complies
Odor
Characteristic
Complies
Extract Ratio
10:01
Complies
Sieve analysis
100% pass 80 mesh
Complies
Loss on Drying
≤5.0%
2.98%
Residue on Ignition
≤5.0%
2.32%
Heavy Metal
<10ppm
Complies
As
<2ppm
Complies
Residual Solvents
Eur.Pharm.
Complies
Microbiology
Total Plate Count
<1000/g
145/g
Yeast & Mold
<100/g
62/g
E.Coli
Negative
Complies
Salmonella
Negative
Complies
Company Profile Introduction
Recommended supplier
-
VIP1年
- Allmpus Laboratories Pvt Ltd
- Estradiol EP Impurity A 53-16-7 96.56
- Inquiry
- 2024-09-14
-
VIP1年
- Symbiotec Pharma Lab Pvt Ltd
- Estrone 53-16-7 98%
- Inquiry
- 2024-03-13
-
VIP1年
- Alfa Omega Pharma
- 53-16-7 Estrone 98%
- Inquiry
- 2024-02-17
-
VIP1年
- Allmpus Laboratories Pvt Ltd
- 53-16-7 Ethinylestradiol EP Impurity C/Estrone 95.02
- Inquiry
- 2024-09-14
- Since:2019-07-05
- Address: Federation business plaza, qiaoxi district, shijiazhuang city, hebei province